Irvine, California-based Global Discovery Biosciences (GD Biosciences) announced the American College of Cardiology published a patient case study online at ACC.org as part of the Diabetes and Cardiometabolic Disease Clinical Topic Collection demonstrating the detection of sub-clinical coronary artery disease (CAD) in a 46 year old male.
Heart disease remains the leading cause of death and disability in the U.S. despite recent improvements in disease management. The PULS Cardiac Test has received significant attention within the medical community as an effective diagnostic tool that allows physicians to identify patients with subclinical, asymptomatic heart disease, who may otherwise be unaware they are at risk of experiencing an acute cardiac event.
Such was the case with a young, 46-year old veteran who, during a pre-retirement medical evaluation, only reported slight chest pain from a previous war injury. Although all of his conventional cardiac evaluation tests including a stress test were normal, his PULS Cardiac test indicated the patient’s risk of a heart attack was five times the expected for his age and gender group. A subsequent coronary computed tomography angiogram (CCTA) was performed and identified a non-obstructive left anterior descending coronary artery (LAD) lesion with a thin cap necrotic core (vulnerable plaque).
The patient was given pre-op cardiac medications and was scheduled for elective angioplasty. Unfortunately, the patient neglected to start his medications and had a heart attack prior to the angioplasty. Luckily, because he was aware of his condition, he was rapidly transported to the hospital where a rescue stent provided successful re-vascularization and an excellent recovery.
“This is the first case where I informed the patient that he would most likely have a heart attack if we do not intervene. The PULS Cardiac Test played an important role in improving patient care.” commented Dr. Eric Harrison,M.D., FACC.
The PULS Cardiac Test is a blood test that measures the 9 protein biomarkers of the body’s immune response to arterial injury leading to formation of cardiac lesions which can become unstable and might rupture causing a blood clot leading to a heart attack. Unstable lesion rupture is the most common cause of heart attacks (75%), not narrowing of the arteries as is commonly believed.
“The PULS Cardiac Test is unlike any other test because it was developed to detect the body’s immune system response to arterial or endothelial damage. ” said Douglas S. Harrington, M.D., CEO of GD Biosciences. “This allows physicians to better identify the cardiac disease stage and improve patient care.”
For more information and to request testing, visit www.pulstest.com.
About GD Biosciences
Global Discovery Biosciences (GD Biosciences) is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.
The company works with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Our goal is to equip physicians with the tools they need to transform health care – one patient at a time.
About the PULS Cardiac Test
The PULS Cardiac Test is a simple blood test that uses breakthrough medical technology to identify individuals with active, yet undetected subclinical Coronary Heart Disease (CHD), who are at risk of experiencing a Heart Attack, and for whom early intervention can help. The test uses 9 clinically-significant protein biomarkers to measure the body’s immune system response to arterial injury leading to the formation of unstable cardiac lesions – the cause of 75% of all Heart Attacks.
Check out our recent news coverage:
Fox News Special Report – Technology Helps Predict Heart Attacks
Travel Pulse – Could Blood Test Warn Pilots of Heart Attack Risk?
Times Colonist – Blood test can assess Heart Attack risk, conference told
Saskatoon Star Phoenix – New test for Heart Attack risk
The Province – Blood test can assess Heart Attack risk, Vancouver conference hears
MEDIA CONTACT:
Adam Farragut
PR Firm: The Publicity Agency
Email: Phone: 813-708-1220 x7778
Website: www.thepublicityagency.com
SOURCE: GD Biosciences
This press release is distributed by PR NewsChannel. Your News. Everywhere.
